News
-
-
-
COMMUNIQUÉ DE PRESSE
Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides
NanoViricides files RPDD application for NV-387 as Measles treatment with US FDA, potentially eligible for PRV upon approval. Addressing rising Measles cases, vaccination challenges -
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete
NanoViricides, Inc. announces completion of manufacture for NV-387 Oral Gummies clinical trial. President to present at NIBA conference. Lead drug NV-387 to target various viral infections -